Pub Date : 2019-02-11DOI: 10.15406/jcpcr.2019.10.00383
E. Oktay
{"title":"Clinicopathologic impact of tumor location in all stages of colorectal cancer","authors":"E. Oktay","doi":"10.15406/jcpcr.2019.10.00383","DOIUrl":"https://doi.org/10.15406/jcpcr.2019.10.00383","url":null,"abstract":"","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"12 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91484428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-09DOI: 10.15406/jcpcr.2018.09.00381
Rida Altaf, J. Kumi-Diaka, R. Branly
Cancer is a complex disease that occurs as a result of accumulated mutations, genetic instability, and altered cellular metabolism, contributing to malignant transformation and to the initiation, growth, and maintenance/proliferation of tumors.1 Prostate cancer (PCa) is still the most common non-skin cancer among men in the United States.2 The American Cancer Society has estimated 164,690 new cases and 29,430 deaths from prostate cancer for 2018.3 The standard treatment modalities (surgery, radio-chemotherapy, hormonal therapy) have been effective in improving the lifestyle of patients. Although the locally confined disease is treatable, treatment of the metastasized prostate cancer is still incurable with mostly guarded prognosis.4,5 The development of resistance to both radiation and chemotherapy has limited the efficacy of current therapeutic interventions for PCa. This has necessitated the search for novel and safer alternative therapeutic regimens. One way to circumvent potential treatment-induced resistance is combination treatment, using two or more therapies that may be mutually inclusive or exclusive in terms of their mechanism of actions.
{"title":"Irradiation augmentation of genistein-induced apoptosis in androgen-independent DU-145 prostate cancer cells in vitro","authors":"Rida Altaf, J. Kumi-Diaka, R. Branly","doi":"10.15406/jcpcr.2018.09.00381","DOIUrl":"https://doi.org/10.15406/jcpcr.2018.09.00381","url":null,"abstract":"Cancer is a complex disease that occurs as a result of accumulated mutations, genetic instability, and altered cellular metabolism, contributing to malignant transformation and to the initiation, growth, and maintenance/proliferation of tumors.1 Prostate cancer (PCa) is still the most common non-skin cancer among men in the United States.2 The American Cancer Society has estimated 164,690 new cases and 29,430 deaths from prostate cancer for 2018.3 The standard treatment modalities (surgery, radio-chemotherapy, hormonal therapy) have been effective in improving the lifestyle of patients. Although the locally confined disease is treatable, treatment of the metastasized prostate cancer is still incurable with mostly guarded prognosis.4,5 The development of resistance to both radiation and chemotherapy has limited the efficacy of current therapeutic interventions for PCa. This has necessitated the search for novel and safer alternative therapeutic regimens. One way to circumvent potential treatment-induced resistance is combination treatment, using two or more therapies that may be mutually inclusive or exclusive in terms of their mechanism of actions.","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"180 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89066765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-08DOI: 10.15406/jcpcr.2018.09.00380
H. Anis
including drugs which can either be dissolved or encapsulated within them forming a nanoparticle and a Nano capsule respectively. The delivered therapeutic proteins or drugs act by altering defective proteins or genes in the patient’s cells. The size of the polymer nanoparticle could be tuned to enable these drugs and therapeutic protein to fit in. PNPs, like all nanoparticles are capable of regaining their size once inside the cell through the physiological change in pH. They are also great candidates for gene delivery, because they are highly stable and they offer controlled release of active ingredients.
{"title":"Gene therapy in the era of nanotechnology/a review of current data","authors":"H. Anis","doi":"10.15406/jcpcr.2018.09.00380","DOIUrl":"https://doi.org/10.15406/jcpcr.2018.09.00380","url":null,"abstract":"including drugs which can either be dissolved or encapsulated within them forming a nanoparticle and a Nano capsule respectively. The delivered therapeutic proteins or drugs act by altering defective proteins or genes in the patient’s cells. The size of the polymer nanoparticle could be tuned to enable these drugs and therapeutic protein to fit in. PNPs, like all nanoparticles are capable of regaining their size once inside the cell through the physiological change in pH. They are also great candidates for gene delivery, because they are highly stable and they offer controlled release of active ingredients.","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77226866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.15406/jcpcr.2019.10.00410
K. Elboukhari
A 38 years old man presented a Black nodule on the face, which appears since childhood and was growing up 02 months before the consultation. It was painless and without pruritus. The dermatological examination showed a sessile-based nodule flesh-colored in places and black in others it was localized under the lower left eyelid. Dermoscopy showed typical ovoid nests and thick arborizing vessels. In front of this clinico dermoscopic panel, pigmented basal cell carcinoma was evoked. Histologic examination showed a proliferation of tumors connected to the epidermis, arranged in masse and made of regular cuboid cells presenting monomorphic nuclei with fine finely nucleated chromatin and an abundant basophilic cytoplasm. Massifs and spans are sometimes centered on cavities filled with eosinophilic material. The tumor cells are pigmented and the mitoses were rare (Figure 1–3).
{"title":"Pigmented eccrine poroma mimicking a pigmented basal cell carcinoma","authors":"K. Elboukhari","doi":"10.15406/jcpcr.2019.10.00410","DOIUrl":"https://doi.org/10.15406/jcpcr.2019.10.00410","url":null,"abstract":"A 38 years old man presented a Black nodule on the face, which appears since childhood and was growing up 02 months before the consultation. It was painless and without pruritus. The dermatological examination showed a sessile-based nodule flesh-colored in places and black in others it was localized under the lower left eyelid. Dermoscopy showed typical ovoid nests and thick arborizing vessels. In front of this clinico dermoscopic panel, pigmented basal cell carcinoma was evoked. Histologic examination showed a proliferation of tumors connected to the epidermis, arranged in masse and made of regular cuboid cells presenting monomorphic nuclei with fine finely nucleated chromatin and an abundant basophilic cytoplasm. Massifs and spans are sometimes centered on cavities filled with eosinophilic material. The tumor cells are pigmented and the mitoses were rare (Figure 1–3).","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87713115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-11DOI: 10.15406/jcpcr.2018.09.00378
S. Shilpi, Roshni Shivvedi, Amrita Singh, Anil Kumar, G. Saraogi, V. Jain, K. Khatri
Vitamin-C also known as ascorbic acid and it is a water-soluble antioxidant and enzyme cofactor present in plants and some animals. Unlike most mammals, humans do not have the ability to synthesize this nutrient endogenously and, therefore, obtain it through diet. Ascorbic acid (AA) is a primary antioxidant remains in human plasma.1 While numerous animal and cell studies have shown beneficial anti-oxidant effects of AA. It is a chain breaking antioxidant and it give their effect by reacting with oxygen, hydroxyl, and superoxide radicals of the substances. It react with radicals of tocopheroxy to re-generate vitamin E.2 There are 2 chemical forms of Vitamin-C: the reduced form (ascorbic acid; AA) and the oxidized form (dehydroascorbic acid; DHA) (Figure 1).1,2
{"title":"Vitamin-C: properties, function and application in cancer therapy","authors":"S. Shilpi, Roshni Shivvedi, Amrita Singh, Anil Kumar, G. Saraogi, V. Jain, K. Khatri","doi":"10.15406/jcpcr.2018.09.00378","DOIUrl":"https://doi.org/10.15406/jcpcr.2018.09.00378","url":null,"abstract":"Vitamin-C also known as ascorbic acid and it is a water-soluble antioxidant and enzyme cofactor present in plants and some animals. Unlike most mammals, humans do not have the ability to synthesize this nutrient endogenously and, therefore, obtain it through diet. Ascorbic acid (AA) is a primary antioxidant remains in human plasma.1 While numerous animal and cell studies have shown beneficial anti-oxidant effects of AA. It is a chain breaking antioxidant and it give their effect by reacting with oxygen, hydroxyl, and superoxide radicals of the substances. It react with radicals of tocopheroxy to re-generate vitamin E.2 There are 2 chemical forms of Vitamin-C: the reduced form (ascorbic acid; AA) and the oxidized form (dehydroascorbic acid; DHA) (Figure 1).1,2","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83568286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-11DOI: 10.15406/jcpcr.2018.09.00376
W. Onuigbo
{"title":"Topographical study of albino nasal cancer in a developing community","authors":"W. Onuigbo","doi":"10.15406/jcpcr.2018.09.00376","DOIUrl":"https://doi.org/10.15406/jcpcr.2018.09.00376","url":null,"abstract":"","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76447956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-10DOI: 10.15406/JCPCR.2018.09.00374
A. Cuc
I am just furious, when my girl-friend with Age 65+ she ist suddenly needless dying on the pneumologic Carcinom – when she was smoking and with sometimes pneumologic insufficiency – but thatfor she regularly was going to the Pneumologic Ambulance to control. But the Pneumolog was regularly controlling only Lungs – Volume Capacity and rustling of her Lungs, but he was never sent her to pneumologic RTG imaging each 2years, despite it must be logically and periodically, but he never did nor at once RTG in duration for last 5years! When Patient has dramatic pains – freguently the carcinom was out of possibilities of surgeon Treatments, because in duration growing about 1,5years there are los of cca half the Lung functional tissue....and after next 5months of beginning dramatic Treatments with combined radiation and chemotherapy without regularly intermediately timing controls after scanning result each 6 weeks at least – the Pneumologic Clinic evidenced to late and frequent despairing fatal Results. In just time the oncologic Patients is with more worse todays rest Health status in probable with comparison to absence a like hood type of the used unapt prolonged Treatments!
{"title":"The artificial intelligence could help in prevency and treatments carcinoms","authors":"A. Cuc","doi":"10.15406/JCPCR.2018.09.00374","DOIUrl":"https://doi.org/10.15406/JCPCR.2018.09.00374","url":null,"abstract":"I am just furious, when my girl-friend with Age 65+ she ist suddenly needless dying on the pneumologic Carcinom – when she was smoking and with sometimes pneumologic insufficiency – but thatfor she regularly was going to the Pneumologic Ambulance to control. But the Pneumolog was regularly controlling only Lungs – Volume Capacity and rustling of her Lungs, but he was never sent her to pneumologic RTG imaging each 2years, despite it must be logically and periodically, but he never did nor at once RTG in duration for last 5years! When Patient has dramatic pains – freguently the carcinom was out of possibilities of surgeon Treatments, because in duration growing about 1,5years there are los of cca half the Lung functional tissue....and after next 5months of beginning dramatic Treatments with combined radiation and chemotherapy without regularly intermediately timing controls after scanning result each 6 weeks at least – the Pneumologic Clinic evidenced to late and frequent despairing fatal Results. In just time the oncologic Patients is with more worse todays rest Health status in probable with comparison to absence a like hood type of the used unapt prolonged Treatments!","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"22 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83743346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-03DOI: 10.26717/BJSTR.2018.11.002131
A. Hague
{"title":"How the cure for cancer was discovered","authors":"A. Hague","doi":"10.26717/BJSTR.2018.11.002131","DOIUrl":"https://doi.org/10.26717/BJSTR.2018.11.002131","url":null,"abstract":"","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88474439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-28DOI: 10.15406/JCPCR.2018.09.00373
A. Fymat
The vast majority of cancer cases are due to environmental risk factors, many of which (but not all) being controllable lifestyle choices and thus preventable. It has been suggested that more than 30% of cancer deaths could be prevented by avoiding risk factors including: tobacco, overweight, obesity, insufficient or/and inappropriate diet, physical inactivity, alcohol, transmitted infections, and air and water pollution. However, not all environmental causes are controllable such as naturally occurring background electromagnetic radiation. This article is concerned with those cancers that are due to genetics. In a companion article, I will discuss the case of cancers caused by epigenetics and ecogenetics and their oncological treatments (which I shall refer to as oncoepigenomics and oncoecogenomics, respectively).
{"title":"Oncogenomics: a personalized cancer therapy","authors":"A. Fymat","doi":"10.15406/JCPCR.2018.09.00373","DOIUrl":"https://doi.org/10.15406/JCPCR.2018.09.00373","url":null,"abstract":"The vast majority of cancer cases are due to environmental risk factors, many of which (but not all) being controllable lifestyle choices and thus preventable. It has been suggested that more than 30% of cancer deaths could be prevented by avoiding risk factors including: tobacco, overweight, obesity, insufficient or/and inappropriate diet, physical inactivity, alcohol, transmitted infections, and air and water pollution. However, not all environmental causes are controllable such as naturally occurring background electromagnetic radiation. This article is concerned with those cancers that are due to genetics. In a companion article, I will discuss the case of cancers caused by epigenetics and ecogenetics and their oncological treatments (which I shall refer to as oncoepigenomics and oncoecogenomics, respectively).","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74632833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-19DOI: 10.15406/jcpcr.2018.09.00371
Y. Saleh, Waleed Hammam
Ovarian cancer is considered the 4th most common cause of cancer-related deaths in women, with an about 200.000 new cases and 125.000 deaths occurring yearly all over the world. Symptoms diagnosing the disease are non-specific, including abdominal discomfort or fullness, dyspepsia and bloating, which may be similar to other conditions thus resulting in a delay in diagnosis.1 About 90% of all ovarian cancers are epithelial ovarian cancer (EOC) and arising from the ovarian surface epithelium or mullerian derivatives.2 EOC is highly curable when it is confined to the ovaries, with expected 5-year survival up to 90%. However, it is rarely diagnosed at an early stage because the disease causes few specific symptoms when it is localized to the ovary. More than 70% with EOC present with advanced stage III or IV, which is associated with high morbidity and mortality.3 Current management of advanced disease includes surgical tumor debulking, followed by adjuvant platinum-and taxane-based chemother apy.4 An approach to improve the outcome of treatment in EOC has focused on modifying the dose, sched ule and route of administration of chemotherapy. The use of intra-peritoneal chemotherapy has been reported to improve outcomes although, an increase in the toxicity.5 Recently, the administration of intravenous (IV) pacli taxel on a weekly schedule improves PFS and OS.6 Another recently approach is the administration of chemotherapy in the neoadjuvant setting, before surgical resection in contrast to conven tional postoperative chemotherapy. Although it is associated with optimal cytoreduction and lower postoperative adverse events, it did not improve OS.7 Therefore, the combination of carboplatin and paclitaxel remains the standard chemo therapy regimen in advanced ovarian cancer, however, OS for patients with advanced disease is poor and the 5-year survival is only 27%.8 Also, the majority of women with advanced stages recur within 5 years with emerging a drug resistance.3 Angiogenesis was found contributing to solid-tumor growth and metastasis.9 EOC cell lines were found frequently expressing the VEGF.10 In literatures, high serum VEGF levels correlated with a higher risk of death or recurrence in ovarian cancer.11 Also, it has been implicated in the peritoneal dissemination and development of malignant ascites12 which is inversely linked with survival.13,14
{"title":"Addition of bevacizumab to adjuvant chemotherapy paclitaxel and carboplatin for cancer ovary. is there a difference?","authors":"Y. Saleh, Waleed Hammam","doi":"10.15406/jcpcr.2018.09.00371","DOIUrl":"https://doi.org/10.15406/jcpcr.2018.09.00371","url":null,"abstract":"Ovarian cancer is considered the 4th most common cause of cancer-related deaths in women, with an about 200.000 new cases and 125.000 deaths occurring yearly all over the world. Symptoms diagnosing the disease are non-specific, including abdominal discomfort or fullness, dyspepsia and bloating, which may be similar to other conditions thus resulting in a delay in diagnosis.1 About 90% of all ovarian cancers are epithelial ovarian cancer (EOC) and arising from the ovarian surface epithelium or mullerian derivatives.2 EOC is highly curable when it is confined to the ovaries, with expected 5-year survival up to 90%. However, it is rarely diagnosed at an early stage because the disease causes few specific symptoms when it is localized to the ovary. More than 70% with EOC present with advanced stage III or IV, which is associated with high morbidity and mortality.3 Current management of advanced disease includes surgical tumor debulking, followed by adjuvant platinum-and taxane-based chemother apy.4 An approach to improve the outcome of treatment in EOC has focused on modifying the dose, sched ule and route of administration of chemotherapy. The use of intra-peritoneal chemotherapy has been reported to improve outcomes although, an increase in the toxicity.5 Recently, the administration of intravenous (IV) pacli taxel on a weekly schedule improves PFS and OS.6 Another recently approach is the administration of chemotherapy in the neoadjuvant setting, before surgical resection in contrast to conven tional postoperative chemotherapy. Although it is associated with optimal cytoreduction and lower postoperative adverse events, it did not improve OS.7 Therefore, the combination of carboplatin and paclitaxel remains the standard chemo therapy regimen in advanced ovarian cancer, however, OS for patients with advanced disease is poor and the 5-year survival is only 27%.8 Also, the majority of women with advanced stages recur within 5 years with emerging a drug resistance.3 Angiogenesis was found contributing to solid-tumor growth and metastasis.9 EOC cell lines were found frequently expressing the VEGF.10 In literatures, high serum VEGF levels correlated with a higher risk of death or recurrence in ovarian cancer.11 Also, it has been implicated in the peritoneal dissemination and development of malignant ascites12 which is inversely linked with survival.13,14","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84959002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}